Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Notification

December 2015: AWMSG approvals

The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use in NHS Wales:

  • Cetuximab (Erbitux; Merck Serono) for the first-line treatment of epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or the chemotherapy regimen FOLFOX.
  • Ivacaftor (Kalydeco; Vertex) for cystic fibrosis (CF) in patients aged 6 years and older who have mutations in the CF transmembrane conductance regulator gene.

For both treatments, the approved patient access scheme should be used. Full details of restrictions are available from the AWMSG website.

 

Citation: The Pharmaceutical Journal URI: 20200428

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.